EUVIMEDEUVIMED entdecken
Leitlinie

RWD16 HYPERTENSION CONTROL IN TREATED U.S. CANCER SURVIVORS UNDER THE 2017 ACC/AHA GUIDELINE: AN ANALYSIS OF NHANES 2011-2023

Hanan Alluhaydan, Tewodros Eguale, Irene Murimi-Worstell

Value in Health · 2026-06 · 29 (6) · S406

DOI: 10.1016/j.jval.2026.03.2005 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Value in Health, 2026-06. Verfasst von Hanan Alluhaydan und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Alluhaydan, H., Eguale, T., & Murimi-Worstell, I. (2026). RWD16 HYPERTENSION CONTROL IN TREATED U.S. CANCER SURVIVORS UNDER THE 2017 ACC/AHA GUIDELINE: AN ANALYSIS OF NHANES 2011-2023. Value in Health, 29(6), S406. https://doi.org/10.1016/j.jval.2026.03.2005

Vancouver

Alluhaydan H, Eguale T, Murimi-Worstell I. RWD16 HYPERTENSION CONTROL IN TREATED U.S. CANCER SURVIVORS UNDER THE 2017 ACC/AHA GUIDELINE: AN ANALYSIS OF NHANES 2011-2023. Value in Health. 2026;29(6):S406. doi:10.1016/j.jval.2026.03.2005

BibTeX
@article{Alluhaydan2026,
  author = {Alluhaydan, Hanan and Eguale, Tewodros and Murimi-Worstell, Irene},
  title = {RWD16 HYPERTENSION CONTROL IN TREATED U.S. CANCER SURVIVORS UNDER THE 2017 ACC/AHA GUIDELINE: AN ANALYSIS OF NHANES 2011-2023},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S406},
  doi = {10.1016/j.jval.2026.03.2005}
}
Kostenlos starten →